Housing and healthcare connection highlighted in Winooski
A soon-to-be-completed three family home on Hall st. in Winooski will help house Vermont's most vulnerable, and it's all thanks to a partnership between the two groups.
'Housing is a key aspect of our patient wellness,' says Maureen Leahy, volunteer with Habitat for Humanity and director of network department psychiatry at UVM Medical Center.
She says patients who have secure housing have a significantly better ability to manage wellness and handle illness.
'Our contribution to housing in our local communities is a direct contribution to our patients wellness,' says Leahy.
Once complete, volunteer manager Caitlyn Conibear says the energy efficient units will house three partner families.
'They'll get to come in, see what it takes to build a home, and then live in a new, healthy home,' Conibear explains.
The project is slated to wrap up by mid-June.
Green Mountain Habitat for Humanity will host more of what they've dubbed 'Wellness Builds' throughout the summer and into the fall – and they're inviting health network employees to join them in getting their hands dirty.
'We've had these homes and we'd love to put Vermont families in them who need a nice, healthy home.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to ABC22 & FOX44.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Enanta Pharmaceuticals to Participate in September Investor Conferences
WATERTOWN, Mass., August 21, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, 2025 at 8:35 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside Chat on Tuesday, September 9, 2025 at 2:00 p.m. ET Baird 2025 Global Healthcare Conference: Fireside Chat on Wednesday, September 10, 2025 at 12:15 p.m. ET A live webcast of each event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at A replay of the webcasts will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@
Yahoo
18 minutes ago
- Yahoo
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming investment and medical conferences: Investment Conferences Cantor Global Healthcare Conference (New York)Fireside Chat Sept. 5 8:00 am ET + 1x1 meetings H.C. Wainwright Global Investment Conference (New York)Presentation Sept. 8 3:30 pm ET + 1x1 meetings Morgan Stanley Global Healthcare Conference (New York)Fireside Chat Sept. 10 7:00 am ET + 1x1 meetings Medical/Scientific Conferences Obesity Science & Innovation (Boston)Keynote Panel Sept. 16 9:10 am ETTitle: Pipeline priorities - exploring leading and emerging targets shaping the future of obesity therapeutics European Association for the Study of Diabetes Annual Meeting (EASD) (Vienna, Austria)Oral Presentation Sept. 19 10:15 am CETTitle: A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 receptor antibody in subjects with metabolic associated fatty liver disease (MAFLD) Available webcasts will be accessible on Skye's website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTSInvestor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@ 234-3889 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action and (v) statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking in to access your portfolio
Medscape
20 minutes ago
- Medscape
Alzheimer's Med Continues to Deliver Benefit at 3 Years
Data from the TRAILBLAZER-ALZ 2 long-term extension (LTE) study demonstrated that donanemab (Kisunla, Eli Lilly and Company) continues to deliver meaningful benefits that increase over 3 years, especially when started early, with a manageable safety profile. 'There was a 27% reduced risk of progression if you were started initially in the trial versus delayed in the trial,' reported study investigator Mark Mintun, MD, group vice president of Neuroscience Research & Development at Eli Lilly and Company. The core TRAILBLAZER-ALZ 2 study results were presented 2 years ago at the Alzheimer's Association International Conference (AAIC) and simultaneously published in JAMA . The most recent results were presented on July 30 at the AAIC 2025. Ongoing Disease-Modifying Effects Participants in the core study who completed the 76-week placebo-controlled period were eligible to continue in the LTE period, lasting an additional 78 weeks. The LTE study included 550 'early-start' participants who initiated donanemab in the core study and either continued it or were switched to placebo after meeting predefined amyloid clearance thresholds. These participants were followed in the LTE period to assess the long-term safety and durability of treatment effects. The LTE study also included 657 'delayed-start' participants who received placebo in the core study and switched to donanemab at the start of the LTE period in a blinded manner to evaluate delayed treatment outcomes. Compared with a matched, untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative, patients initially treated with donanemab in the core study had a reduction in cognitive decline at 18 months of 0.6 points on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) — and this benefit grew to 1.2 points at 36 months. 'What we saw was that the benefits continued to grow and ended up essentially doubling with a benefit of 1.2 CDR sum of boxes versus the control arm at the end of the 3-year trial,' Mintun told conference attendees. Nearly half of patients in the delayed donanemab start group had progressed to moderate Alzheimer's disease (AD) by the time they started treatment in the LTE period. Despite this, they still achieved a 0.8 CDR-SB benefit after 3 years. Compared with delayed start, early start reduced the risk for progression on the CDR global scale by 27%, Mintun noted. Amyloid clearance was consistent across groups. More than three quarters of patients treated with donanemab reached amyloid clearance within 76 weeks of starting treatment. Long-term follow-up showed slow reaccumulation of amyloid of about 2.5 CL/y. No new safety signals were observed in the LTE period. Safety outcomes were similar across the early- and delayed-start groups. Amyloid-related imaging abnormalities (ARIA) and infusion-related events occurred at comparable rates whether treatment was started early or delayed. Encouraging Confirmation Reached for comment, Eric Reiman, MD, executive director at the Banner Alzheimer's Institute, Phoenix, said it's 'encouraging to see confirmation of the view that many in the field have is that these treatments will continue to show a greater benefit when followed over longer periods of time, and that starting earlier is likely to be better, as we would have expected.' The observed pattern of continued benefit over time 'supports the concept of a disease-modifying treatment, rather than purely a symptomatic treatment,' Reiman told Medscape Medical News . Also providing perspective, Rebecca M. Edelmayer, PhD, Alzheimer's Association vice president of Scientific Engagement, said a key message is to 'diagnose and treat Alzheimer's disease early to get the most benefit.' 'Patients in the study who were treated in earlier stages of disease progression exhibited greater and increasing benefits compared to those with delayed treatment or no treatment. Patients at earlier disease stages and younger patients experienced more pronounced benefits,' said Edelmayer. She also noted that stopping donanemab once the patient achieves amyloid clearance is a 'feasible treatment strategy [and] may reduce patient and healthcare provider/system burden. Close monitoring and ongoing surveillance remain essential, including MRI monitoring for ARIA, especially in APOE-ε4 carriers. New titration guidelines and FDA guidance designed to reduce ARIA risk improve the safety profile of the treatment,' Edelmayer said. Edelmayer also emphasized the importance of collecting real-world data outside of what can typically be learned through clinical trials. 'The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) collects real-world data from patients receiving care across a variety of clinical settings who are being evaluated for or treated with new, approved Alzheimer's treatments. The evidence gathered will be used to advance research, improve health equity and patient care, and inform Alzheimer's and other dementia treatment practices,' Edelmayer said. 'The data gathered can be used by professional and nonprofessional care providers, diagnostic companies, EHR companies, private and public funders, researchers, life sciences companies, payors, public health, and government and regulatory policymakers to improve care,' she added. ALZ-NET is now enrolling clinical sites across the country.
